Historie von Umsatz, Gewinn und Cashflow aus den offiziellen Geschäftsberichten.
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep.
Interaktive Charts und vollständige Abschlüsse ansehen → Bewertungsmodell (DCF) →
| Gewinn- und Verlustrechnung | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gesamtumsatz | $9.5B | $9.5B | $9.3B | $8.5B | $8.1B | $7.8B | $6.7B | $6.3B | $5.8B | $5.3B | $4.9B | $4.8B | $4.8B | $4.6B | $4.3B | $4.2B | $3.6B | $2.8B |
| Bruttoergebnis | $6.7B | $6.7B | $6.4B | $5.8B | $5.5B | $5.3B | $4.5B | $4.1B | $3.8B | $3.4B | $3.1B | $3.0B | $3.0B | $2.8B | $2.7B | $2.5B | $2.1B | $1.7B |
| Bruttomarge % | 70.9% | 70.5% | 69.1% | 68.3% | 67.8% | 68.3% | 66.8% | 65.7% | 65.2% | 64.9% | 64.3% | 62.3% | 62.9% | 62.1% | 62.7% | 60.0% | 58.2% | 61.7% |
| Betriebsergebnis (EBIT) | $3.6B | $3.6B | $3.4B | $3.1B | $2.9B | $2.8B | $2.3B | $2.0B | $1.9B | $1.7B | $1.4B | $1.1B | $970M | $821M | $854M | $684M | $309M | $281M |
| Operative Marge % | 37.6% | 38.0% | 36.6% | 35.9% | 36.2% | 36.0% | 34.0% | 32.2% | 32.3% | 32.5% | 28.7% | 22.7% | 20.3% | 18.0% | 19.7% | 16.2% | 8.6% | 10.2% |
| Jahresüberschuss | $2.6B | $2.7B | $2.5B | $2.3B | $2.1B | $2.0B | $1.6B | $1.5B | $1.4B | $864M | $821M | $339M | $583M | $504M | $436M | $245M | $110M | ($100M) |
| Nettomarge % | 27.5% | 28.2% | 26.9% | 27.4% | 26.2% | 26.2% | 24.5% | 24.0% | 24.5% | 16.3% | 16.8% | 7.1% | 12.2% | 11.1% | 10.1% | 5.8% | 3.1% | -3.6% |
| EBITDA | — | $4.1B | $3.9B | $3.7B | $3.4B | $3.2B | $2.7B | $2.5B | $2.2B | $1.9B | $1.6B | $868M | $1.1B | $1.0B | $941M | $635M | $400M | $2M |
| Ergebnis je Aktie (EPS) | $6.07 | $6.02 | $5.47 | $5.07 | $4.49 | $4.27 | $3.42 | $3.11 | $2.93 | $1.75 | $1.65 | $0.68 | $1.16 | $1.01 | $0.87 | $0.51 | $0.23 | $-0.21 |
| Ausstehende Aktien (Mio.) | — | 444M | 455M | 462M | 470M | 477M | 479M | 482M | 487M | 493M | 498M | 502M | 502M | 500M | 500M | 482M | 482M | 482M |
Quelle: veröffentlichte Unternehmensberichte (SEC). Bitte prüfen Sie die Zahlen vor Verwendung auf SEC EDGAR.
Bilanzen, Cashflow-Rechnungen, Quartalsdaten und alle Kennzahlen finden Sie im interaktiven Viewer für ZTS. /companies/us/ZTS
Die Informationen auf dieser Website dienen ausschließlich Bildungs- und Informationszwecken und stellen keine Anlageberatung dar. Es werden keine Kursziele und keine Anlageurteile veröffentlicht.
About TickerBase · Data methodology & sources · Privacy · Terms